☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - March 2022

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Hydrocortisone modified-release (Efmody®) has been rejected for use in the treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults. The manufacturer did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

Betula verrucosa extract (Itulazax®) has been rejected for use in the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. The manufacturer did not make a submission for this indication.

Solriamfetol (Sunosi®) has been rejected for use in adult patients with obstructive sleep apnoea (OSA) to improve wakefulness and reduce excessive daytime sleepiness when these symptoms have not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). The manufacturer did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - March 2022' by emailShare 'SMC Update - March 2022' on FacebookShare 'SMC Update - March 2022' on TwitterShare 'SMC Update - March 2022' on LinkedInShare 'SMC Update - March 2022' on reddit

atomic-wealth

No Comments to “SMC Update - March 2022”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

governor
governor
governor
governor